1-in-5 children worldwide still don’t receive even basic vaccines (WHO), and 1.5 million die every year from vaccine-preventable diseases. We have a solution. We develop active vaccines as dry powders. Dry powder formulations significantly reduce the cost of transporting and storing vaccines in a refrigerated Cold Chain in the critical last mile before administration. Read more
Virus-by-virus, protein-by-protein, we’re developing a new generation of unique dry-powder versions of many of the world’s most advanced biologics. We aim to seek patents on all of them. In a market forecast to be worth 25 BUSD by 2021, access to our patents will deliver a formidable competitive advantage. Read more
New injectable biologic therapies are highly targeted and effective. Yet for many they remain unstable and inconvenient to transport and administer. One important reason is that 80% of biologics are still formulated as liquids. We have a solution. New dry-powder biologic treatments will be easier to both transport and take on the move—and more affordable. Read more
Adenovirus is a central ingredient in vaccines being developed against Malaria, Ebola, meningitis and HIV. A dry powder version requiring no end-to-end refrigeration could democratize access to vaccines worldwide. Our dry powder Adenovirus stays active at 40°C for over a week. No refrigeration or freezing required. It is currently awaiting patent. Read more